[go: up one dir, main page]

BR0308860A - Fator viii modificado - Google Patents

Fator viii modificado

Info

Publication number
BR0308860A
BR0308860A BR0308860-0A BR0308860A BR0308860A BR 0308860 A BR0308860 A BR 0308860A BR 0308860 A BR0308860 A BR 0308860A BR 0308860 A BR0308860 A BR 0308860A
Authority
BR
Brazil
Prior art keywords
factor viii
fviii
modified factor
viii
immunogenic
Prior art date
Application number
BR0308860-0A
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Francis J Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0308860A publication Critical patent/BR0308860A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"FATOR VIII MODIFICADO". A presente invenção refere-se à modificação de Fato VIII humano (FVIII) para resultar em proteínas FVIII que são substancialmente não-imunogênicas ou menos imunogênicas que qualquer correspondente não-modificado quando utilizado in vivo. A invenção refere-se ainda aos peptídeos do epitopo de células T derivados da dita proteína não-modificada por meio dos quais é possível criar variações modificadas do FVIII com imunogenicidade reduzida.
BR0308860-0A 2002-04-18 2003-04-17 Fator viii modificado BR0308860A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02008712 2002-04-18
EP03006554 2003-03-24
PCT/EP2003/004063 WO2003087161A1 (en) 2002-04-18 2003-04-17 Modified factor viii

Publications (1)

Publication Number Publication Date
BR0308860A true BR0308860A (pt) 2005-01-04

Family

ID=29252205

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308860-0A BR0308860A (pt) 2002-04-18 2003-04-17 Fator viii modificado

Country Status (15)

Country Link
US (1) US20050256304A1 (pt)
EP (1) EP1495052B9 (pt)
JP (1) JP2005538694A (pt)
KR (1) KR20040103970A (pt)
CN (1) CN1646564A (pt)
AT (1) ATE412671T1 (pt)
AU (1) AU2003232482A1 (pt)
BR (1) BR0308860A (pt)
CA (1) CA2482926A1 (pt)
DE (1) DE60324406D1 (pt)
ES (1) ES2319758T3 (pt)
MX (1) MXPA04010061A (pt)
PL (1) PL371278A1 (pt)
RU (1) RU2004133761A (pt)
WO (1) WO2003087161A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2526120A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
HRP20070268B1 (hr) * 2004-11-12 2018-04-20 Bayer Healthcare Llc Ciljana modifikacija faktora viii
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
WO2011060372A2 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
KR102040867B1 (ko) * 2010-10-27 2019-11-07 박스알타 인코퍼레이티드 면역 관용 유도 및 면역진단을 위한 fviii 펩타이드
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス,インク. 改質された毒素
EP2968499A4 (en) * 2013-03-15 2016-11-30 Haplomics Inc COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A
EP3427744A1 (en) 2013-03-15 2019-01-16 Bayer Healthcare LLC Variant factor viii polyleptides and methods of their production and use
JP7274472B2 (ja) 2017-10-05 2023-05-16 エピバックス、インコーポレイテッド 制御性t細胞エピトープ
AU2019253212B2 (en) 2018-04-12 2024-11-14 Biotest Ag De-immunized Factor VIII molecule and pharmaceutical compositions comprising the same
MX2021000582A (es) * 2018-07-16 2021-04-12 Baxalta Inc Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
US20020068303A1 (en) * 1994-07-14 2002-06-06 Ruth Laub Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
AU6486196A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
ATE319745T1 (de) * 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CA2342967A1 (en) * 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Also Published As

Publication number Publication date
MXPA04010061A (es) 2004-12-13
AU2003232482A1 (en) 2003-10-27
ES2319758T3 (es) 2009-05-12
US20050256304A1 (en) 2005-11-17
PL371278A1 (en) 2005-06-13
RU2004133761A (ru) 2005-07-10
KR20040103970A (ko) 2004-12-09
WO2003087161A1 (en) 2003-10-23
EP1495052B9 (en) 2009-12-16
JP2005538694A (ja) 2005-12-22
EP1495052A1 (en) 2005-01-12
EP1495052B1 (en) 2008-10-29
ATE412671T1 (de) 2008-11-15
CN1646564A (zh) 2005-07-27
CA2482926A1 (en) 2003-10-23
DE60324406D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
BR0308860A (pt) Fator viii modificado
BR0012424A (pt) Peptìdeos meningocócicos antigênicos
ATE267211T1 (de) Impfstoff gegen hpv
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
BR9906927A (pt) Proteìnas de neisseria meningitidis
PT1002110E (pt) Respostas imunitarias contra antigenios dos vph suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector deexpressao com aptidao para a expressao destas proteinas
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
EP3263589A3 (en) Peptide sequences and compositions
WO2008020335A3 (en) Immunogenic compositions for streptococcus agalactiae
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
BR0205983A (pt) fármacos peptìdicos antiangiogênicos
WO1999040113A3 (fr) Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques
AR051512A1 (es) Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
KR970704461A (ko) Hla 결합 펩티드 및 그의 용도(hla binding peptides and their uses)
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
AU2001248822A1 (en) Gd3-mimetic peptides
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR0011469A (pt) Gm-csf equina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]